{
    "clinical_study": {
        "@rank": "41693", 
        "arm_group": [
            {
                "arm_group_label": "Mitomycin C", 
                "arm_group_type": "Experimental", 
                "description": "Up to 10 mg administered during each standard of care endoscopic retrograde cholangiography. No more than five mitomycin C applications per every twelve months will be given."
            }, 
            {
                "arm_group_label": "Normal saline", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Given during each standard of care endoscopic retrograde cholangiography. No more than five normal saline applications per every twelve months will be performed."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the effectiveness and safety of mitomycin C in the\n      treatment of primary sclerosing cholangitis (PSC)."
        }, 
        "brief_title": "Mitomycin C Therapy for Patients With Primary Sclerosing Cholangitis", 
        "completion_date": {
            "#text": "September 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Primary Sclerosing Cholangitis", 
        "condition_browse": {
            "mesh_term": [
                "Cholangitis", 
                "Cholangitis, Sclerosing"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ages 18 or older\n\n          -  Previously established diagnosis of primary sclerosing cholangitis\n\n        Exclusion Criteria:\n\n          -  American Society of Anesthesiologists class 4 or greater\n\n          -  Serum creatinine >= 1.7 mg/dL, eGFR <= 30 mL/min, or dialysis dependence\n\n          -  Serum hemoglobin <= 7 g\n\n          -  Left ventricular ejection fraction <= 30%\n\n          -  Dyspnea with minimal exertion (or supplemental oxygen dependence)\n\n          -  History of bone marrow disease\n\n          -  Prior recipient of organ transplantation\n\n          -  Ongoing chemotherapy\n\n          -  Obstruction of the upper GI tract\n\n          -  Pregnant or lactating\n\n          -  Inability to provide informed consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "130", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01688024", 
            "org_study_id": "NA_00052685"
        }, 
        "intervention": [
            {
                "arm_group_label": "Mitomycin C", 
                "intervention_name": "Mitomycin C", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Normal saline", 
                "intervention_name": "Normal saline", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Mitomycins", 
                "Mitomycin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "mitomycin C", 
        "lastchanged_date": "October 8, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21288"
                }, 
                "name": "Johns Hopkins Hospital"
            }, 
            "investigator": {
                "last_name": "Zhiping Li, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 2 Study of Mitomycin C Therapy for Biliary Strictures in Patients With Primary Sclerosing Cholangitis", 
        "overall_contact": {
            "email": "pchen37@jhmi.edu", 
            "last_name": "Po-Hung Chen, M.D.", 
            "phone": "410-614-0950"
        }, 
        "overall_contact_backup": {
            "email": "tworeta1@jhmi.edu", 
            "last_name": "Tinsay A. Woreta, M.D., M.P.H.", 
            "phone": "410-955-2635"
        }, 
        "overall_official": {
            "affiliation": "Johns Hopkins University", 
            "last_name": "Zhiping Li, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Therapeutic Effect on Disease Prognosis as Determined by the Mayo Natural History Model for Primary Sclerosing Cholangitis", 
            "safety_issue": "No", 
            "time_frame": "Two years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01688024"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of Patients with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Two years"
            }, 
            {
                "measure": "Frequency of Endoscopic Interventions Needed to Manage Disease-related Complications", 
                "safety_issue": "No", 
                "time_frame": "Two years"
            }
        ], 
        "source": "Li, Zhiping, M.D.", 
        "sponsors": {
            "collaborator": {
                "agency": "Johns Hopkins University", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Li, Zhiping, M.D.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}